A path from synthesis to emergency use authorization of molnupiravir as a COVID-19 therapy
Author:
Funder
Council of Scientific and Industrial Research, India
University Grants Commission
Publisher
Elsevier BV
Reference123 articles.
1. (a). “Summary of Product Characteristics for Lagevrio”.Medicines and Healthcare products Regulatory Agency(MHRA). 4 November 2021.Archivedfrom the original on 4 November 2021. Retrieved4 November2021; (b). Focosi, D. Molnupiravir: From Hope to Epic Fail?Viruses2022,14, 2560; (c). Pagliano P, Sellitto C, Ascione T, Scarpati G, Folliero V, Piazza O, Franci G, Filippelli A, Conti V. The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19). Expert Opin Drug Discov.2022 Dec;17(12):1299-1311; (d). Yip AJW, Low ZY, Chow VTK, Lal SK. Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity. Viruses. 2022 Jun 20;14(6):1345.
2. Toots, M.; Yoon, J.J.; Cox, R. M.; Hart, M.; Sticher, Z.M.; Makhsous, N. ;Plesker, R. ; Barrena, A.H.; Reddy, P.G.; Mitchell, D.G.; Shean, R.C.; Blueming, G.R.;. Kolykhalov, A.A.; Greninger, A.L.; Natchus, M.G.; Painter, G.R.; Plemper, R.K. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci TranslMed2019, 11(515).
3. Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model;Toots;Translational Research,2020
4. Sheahan,T. P.; Sims, A.C.; Zhou, S.; Graham,R.L.; Pruijssers,A.J.; Agostini, M.L.;Leist,S. R.; Schäfer,A.; Dinnon, K.H.; Stevens, L.J.; Chappell, J.D.; Lu,X.; Hughes, T.M.; George, A.S.; Hill, C.S.; Montgomery,S.A.; Brown,A.J.; Bluemling,G.R.; Natchus, M.G.;Saindane, M.; Kolykhalov, A.A.;Painter,J,; G.;Harcourt,Tamin,A.;Thornburg,N.J.;Swanstrom, R.; . Denison, M.R.; Baric, R.S.; An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med2020, 12(541).
5. Beta-D-N(4)-hydroxycytidine is a potent anti-alphavirus compound that induces high level of mutations in viral genome;Urakova;Journal of Virology,2018
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3